A Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19 Study | National Institute of Environmental Health Sciences
Skip Navigation
A Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19 Study
Close the left navigation
Add
Study Background
This study is no longer accepting participants.
To find studies that are currently recruiting, please visit the
Join an
NIEHS Study
website
For More Information
ClinicalTrials.gov
NIH Clinical Studies
According to the Centers for Disease Control and Prevention, cigarette smoking causes more than 480,000 deaths each year in the United States, which translates to causing nearly one of every five deaths. Although the health impacts of smoking, such as cardiovascular and respiratory disease, cancer, and reduced fertility are well-documented, the goal of the E-Cigs and Smoking Study is to develop new biomarkers of tobacco smoke exposure or e-cigarette use. The biomarkers will be based on analysis of DNA methylation, which is the addition of methyl groups to DNA and is one of several epigenetic processes that occur in cells.
To test this hypothesis, we will establish a bank of cryopreserved peripheral blood mononuclear cells (PBMCs) from before and after COVID-19 exposure from smokers and nonsmokers and use mass cytometry (CyTOF) to analyze detailed immune profiles, test if the frequency of senescent CD8 T cells is higher among smokers who develop COVID-19 (antibody positivity) relative to those who do not develop COVID-19 positivity. To compare potential immunological biomarkers of susceptibility to viral infection with genetic, epigenetic and other biological characteristics measured in blood before and after recovery from COVID-19 illness and develop assays that indicate immune cell dysfunction and COVID-19 susceptibility.
Eligibility Criteria
Healthy men and women ages 30-55
Current cigarette or vaping users
No prior or current cancer diagnosis
A body mass index of less than 35
No prior history of COVID-19 infection
Stated willingness to comply with all study procedures and availability for the duration of the study
Principal Investigator
Stavros Garantziotis, M.D.
Tenure Track Investigator; Immunity, Inflammation, and Disease Laboratory
Tel 984-287-4412
[email protected]
Back
to Top
Last Reviewed: December 30, 2025